结膜黑色素瘤的临床、病理与分子遗传学特征分析
该回顾性病例系列研究纳入70例结膜黑色素瘤患者,分析其临床、影像、病理及BRAF V600E突变特征。结果显示肿瘤多见于中老年单眼,以球结膜及穹隆结膜为主,上皮细胞型常见,复发率27.4%、转移率19.4%、病死率54.8%,伴溃疡或眼眶侵犯者复发率更高,部分BRAF V600E突变患者可从靶向治疗获益。
要点
- 结膜黑色素瘤多见于中老年单眼,球结膜和穹隆结膜最常见。
- 伴溃疡或眼眶侵犯患者复发率显著升高(P=0.026和P=0.002)。
- BRAF V600E突变阳性率36.7%,部分患者BRAF抑制剂治疗有效。
核心结论
- 结膜黑色素瘤多发生于中老年患者单侧眼,以球结膜及穹隆结膜多见,组织病理学以上皮细胞型为主,具有较高的复发及转移率。
- 部分患者具有BRAF V600E突变,可从BRAF抑制剂治疗获益。
研究设计与样本
- 回顾性病例系列研究,纳入西安市人民医院(西安市第四医院)陕西省眼科医院及西安市第一医院2004年1月至2025年6月确诊的结膜黑色素瘤患者70例(70只眼)。
- 收集临床、影像及病理学资料,对部分患者进行BRAF V600E突变检测,采用χ2检验或χ2校正检验进行统计分析。
主要发现
- 患者年龄(60.8±10.6)岁,男性40例(57.1%),女性30例(42.9%),均为单眼患病,左眼33例(47.1%),右眼37例(52.9%)。
- 肿瘤位于球结膜37例(52.9%)、穹隆结膜24例(34.2%)、睑结膜9例(12.9%),侵及眼眶13例(18.6%)、眼球3例(4.3%)、泪囊6例(8.6%)。
- AJCC分期T1期10例(14.3%)、T2期41例(58.6%)、T3期19例(27.1%),伴表面溃疡6例(8.6%)。
- 组织病理学结节型67例(95.7%)、表浅扩散型3例(4.3%),上皮细胞型47例(67.1%)、混合细胞型23例(32.9%),伴黑色素63例(90.0%),伴原发性获得性黑变病32例(45.7%),伴肿瘤浸润淋巴细胞48例(68.6%)。
- 62例(88.6%)获得随访,复发率27.4%(17/62),转移率19.4%(12/62),病死率54.8%(34/62)。
关键数值与推荐
- 伴溃疡患者复发率为4/5,不伴溃疡患者为22.8%(13/57),差异有统计学意义(χ2=4.96,P=0.026)。
- 侵犯眼眶患者复发率为8/13,未侵犯眼眶患者为18.3%(9/49),差异有统计学意义(χ2=9.62,P=0.002)。
- 30例(42.9%)完成BRAF V600E突变检测,其中11例检出点突变,阳性率36.7%。
- 10例(14.3%)接受BRAF抑制剂靶向治疗,7例残留肿物明显缩小且无肿瘤进展,3例无反应并死于疾病进展。
临床怎么用
- 对结膜黑色素瘤患者应关注溃疡及眼眶侵犯等复发高危因素,并加强随访。
- 可考虑对结膜黑色素瘤患者进行BRAF V600E突变检测,以指导靶向治疗选择。
- 手术切除或眼球摘除/眶内容剜除术是主要治疗方式,部分患者可从BRAF抑制剂治疗中获益。
局限性
- 本研究为回顾性病例系列研究,部分患者未完成BRAF V600E突变检测,随访率88.6%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical, pathological and molecular genetic characteristics of conjunctival melanoma (CoM). Methods: A retrospective case series study was conducted. The clinical, imaging and pathological data of patients diagnosed with CoM from January 2004 to June 2025 at Shaanxi Eye Hospital of Xi'an People's Hospital (Xi'an Fourth Hospital) and Xi'an First Hospital were analyzed. Some patients were detected for the BRAF V600E mutation. The χ2 test or the χ2 correction test was used for statistical analysis. Results: A total of 70 patients (70 eyes) with CoM were enrolled, aged (60.8±10.6) years, including 40 males (57.1%) and 30 females (42.9%). There were 33 cases (47.1%) in the left eye and 37 cases (52.9%) in the right eye. The tumor was located at the bulbar conjunctiva in 37 cases (52.9%), at the vault conjunctiva in 24 cases (34.2%), and at the palpebral conjunctiva in 9 cases (12.9%), involving the orbit in 13 cases (18.6%), the eyeball in 3 cases (4.3%), and the lacrimal sac in 6 cases (8.6%). Most patients presented with black nodules or cauliflower-like masses in the conjunctival area. Some tumors were accompanied by superficial vascular hyperplasia and pigmentation of adjacent tissues, while some invaded the cornea or orbit, resulting in clinical manifestations such as visual field defects, exophthalmos and limited movement. Imaging showed irregular soft tissue density shadows at the conjunctival site. According to the criteria of the American Joint Committee on Cancer, the tumor was at the T1 stage in 10 cases (14.3%), T2 stage in 41 cases (58.6%), and T3 stage in 19 cases (27.1%), with superficial ulcers in 6 cases (8.6%). Histopathology results disclosed that 67 cases (95.7%) were of the nodular type, 3 cases (4.3%) were of the superficially diffuse type, 47 cases (67.1%) were of the epithelial cell type, and 23 cases (32.9%) were of the mixed cell type. Sixty-three cases (90.0%) were accompanied by melanin, 32 cases (45.7%) were accompanied by primary acquired melanosis, including 23 cases (32.9%) with atypical primary acquired melanosis and 2 cases (2.9%) with conjunctival nevus, and 48 cases (68.6%) had tumor infiltrating lymphocytes. Immunohistochemistry demonstrated positive melanin markers such as human melanoma-associated antigen 45, melanocyte antigen A, S-100 protein and sex-determining region Y-frame protein 10. Thirty cases (42.9%) completed the detection of BRAF V600E mutations, of which 11 had BRAF V600E point mutations, with a positive rate of 36.7%. Sixty-two patients (88.6%) were followed up, with a recurrence rate of 27.4% (17/62), a metastasis rate of 19.4% (12/62), and a case fatality rate of 54.8% (34/62). The recurrence rate was 4/5 among patients with ulcers, versus 22.8% (13/57) among patients without ulcers (χ2=4.96, P=0.026); it was 8/13 among patients with orbital invasion, versus 18.3% (9/49) among patients without orbital invasion (χ2=9.62, P=0.002). Thirty-four patients (48.5%) underwent complete resection of the ocular mass, 16 (22.9%) underwent partial resection, and 20 (28.6%) underwent ocular or intraorbital enucleation. Ten patients (14.3%) received BRAF inhibitor-targeted therapy. Seven patients had a significant reduction of the residual mass and no tumor progression, and 3 patients did not respond to the treatment and died from the disease progression. Conclusions: CoM mostly occurs in the unilateral eye of middle-aged and elderly patients, more common at the bulbar conjunctiva and fornix conjunctiva, and histopathological epithelial cell types are the main types, with a high recurrence and metastasis rate. 目的: 探讨结膜黑色素瘤(CoM)的临床、病理及分子遗传学特征。 方法: 回顾性病例系列研究。纳入西安市人民医院(西安市第四医院)陕西省眼科医院及西安市第一医院2004年1月至2025年6月确诊CoM患者的临床、影像及病理学资料,并对部分患者进行BRAF V600E突变检测,回顾性分析其临床病理及分子遗传学特征。采用χ2检验或χ2校正检验进行统计学分析。 结果: 共纳入CoM患者70例(70只眼),年龄为(60.8±10.6)岁;男性40例(57.1%),女性30例(42.9%);均为单眼患病,其中左眼33例(47.1%),右眼37例(52.9%),肿瘤位于球结膜37例(52.9%),穹隆结膜24例(34.2%),睑结膜9例(12.9%),侵及眼眶13例(18.6%),侵及眼球3例(4.3%),累及泪囊6例(8.6%)。患者多以发现结膜部位黑色肿物就诊,专科检查多为结膜部位黑色结节状或菜花样肿物,部分伴有表面血管增生及附近组织色素沉着,部分侵及角膜或眼眶,出现视野缺损、眼球突出及运动受限等临床表现;影像学表现为结膜部位不规则软组织密度影。美国癌症联合委员会(AJCC)分期T1期10例(14.3%),T2期41例(58.6%),T3期19例(27.1%),伴有表面溃疡6例(8.6%);组织病理学结节型67例(95.7%),表浅扩散型3例(4.3%),上皮细胞型47例(67.1%),混合细胞型23例(32.9%),伴有黑色素63例(90.0%),无黑色素7例(10.0%),伴有原发性获得性黑变病(PAM)32例(45.7%),其中伴非典型PAM 23例(32.9%),伴有结膜痣2例(2.9%),伴有肿瘤浸润淋巴细胞48例(68.6%);免疫组织化学检测人黑色素瘤相关抗原45、黑色素细胞抗原A、S-100蛋白及性别决定区Y框蛋白10等黑色素标记阳性,30例(42.9%)完成BRAF V600E突变检测,其中11例检测出BRAF V600E点突变,阳性率为36.7%;62例(88.6%)获得随访,复发率为27.4%(17/62),转移率为19.4%(12/62),病死率为54.8%(34/62)。伴溃疡患者的复发率为4/5,不伴溃疡患者的复发率为22.8%(13/57),差异有统计学意义(χ2=4.96,P=0.026),侵犯眼眶患者的复发率为8/13,未侵犯眼眶患者的复发率为18.3%(9/49),差异有统计学意义(χ2=9.62,P=0.002);所有患者均接受眼部肿物手术切除或眼球摘除术,其中34例(48.5%)完全切除,16例(22.9%)部分切除,20例(28.6%)行眼球摘除或眶内容剜除术;10例(14.3%)患者进行了BRAF抑制剂靶向治疗,7例患者残留肿物明显缩小,无肿瘤进展,3例患者治疗无反应,疾病进展死亡。 结论: CoM多发生于中老年患者单侧眼,以球结膜及穹窿结膜多见,组织病理学以上皮细胞型为主,具有较高的复发及转移率,部分患者具有BRAF V600E突变,可从BRAF抑制剂治疗获益。.
引用
- Liu H, Ren YJ, Fu XJ, et al. [Analysis of clinical, pathological and molecular genetic characteristics of conjunctival melanoma]. Zhonghua Yan Ke Za Zhi. 2026. PMID: 41820066. doi:10.3760/cma.j.cn112142-20250425-00203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。